Amlodipine and Valsartan Combined and as Monotherapy in Stage 2, Elderly, and Black Hypertensive Patients: Subgroup Analyses of 2 Randomized, Placebo-Controlled Studies
Version of Record online: 10 MAY 2007
The Journal of Clinical Hypertension
Volume 9, Issue 5, pages 355–364, May 2007
How to Cite
Smith, T. R., Philipp, T., Vaisse, B., Bakris, G. L., Margaret Wernsing, Yen, J. and Glazer, R. (2007), Amlodipine and Valsartan Combined and as Monotherapy in Stage 2, Elderly, and Black Hypertensive Patients: Subgroup Analyses of 2 Randomized, Placebo-Controlled Studies. The Journal of Clinical Hypertension, 9: 355–364. doi: 10.1111/j.1524-6175.2007.06689.x
- Issue online: 10 MAY 2007
- Version of Record online: 10 MAY 2007
- Manuscript received March 2, 2007; revised April 5, 2007; accepted April 9, 2007
- 4American Heart Association. Heart Disease and Stroke Statistics—2006 Update. Dallas, TX: American Heart Association; 2006.
- 17Two randomized, double blind, multicenter, multifactorial, placebo-controlled, parallel-group studies to evaluate the efficacy and safety of valsartan and amlodipine combined and alone in hypertensive patients [published online ahead of print April 2, 2007]. Clin Ther. doi:10.1016/j.clinthera.2007.03.018., , , et al.
- 18Hypertension in African Americans Working Group. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003;163:525–541., , , et al., for the
- 19American Diabetes Association. Hypertension management in adults with diabetes. Diabetes Care. 2004;27(suppl 1):S65–S67., , , for the
- 22The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–2997.